Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 2/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 4/20 | 0.40 |
| ▸ | NOS3 | P29474 | 2/20 | 0.40 |
| ▸ | NOS1 | P29475 | 2/20 | 0.40 |
| ▸ | NOS2 | P35228 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.39 |
| ▸ | TOP2A | P11388 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4967049 | 0.85 | HRH1 (0.59) | HRH1CCR3KCNH2TBK1AR | |
| SCHEMBL5978556 | 0.84 | HRH1 (0.53) | MAP3K5HRH1CCR3KCNH2TBK1 | |
| SCHEMBL27169505 | 0.83 | HRH1 (0.43) | HRH1CCR3KCNH2ARFPR2 | |
| SCHEMBL27169508 | 0.83 | HRH1 (0.43) | HRH1CCR3KCNH2ARFPR2 | |
| Hydrochloric Acid SCHEMBL30872806 | 0.82 | HRH1 (0.42) | HRH1CCR3KCNH2ARFPR2 | |
| SCHEMBL5189891 | 0.82 | HRH1 (0.45) | HRH1CCR3HTR2CHTR2BSLC6A4 | |
| Hydrochloric Acid SCHEMBL180200 | 0.81 | TOP2A (0.44) | HRH1CCR3HTR2CHTR2BSLC6A4 | |
| SCHEMBL22265925 | 0.80 | HRH1 (0.48) | MAP3K5HRH1HTR2AHTR2CHTR2B | |
| SCHEMBL5363977 | 0.80 | NOS2 (0.50) | MAP3K5HTR2CHTR2BNOS3NOS1 | |
| SCHEMBL14453574 | 0.80 | TBK1 (0.47) | MAP3K5HRH1HTR2CHTR2BTBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257365-A1 | SMALL MOLECULE ANDROGEN RECEPTOR PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257365-A1 | SMALL MOLECULE ANDROGEN RECEPTOR PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2023-08-17 | — | — | US | disclosed |
| US-20130023562-A1 | NOVEL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2013-01-24 | — | — | US | disclosed |
| US-8314127-B2 | Piperidine derivatives | ASTRAZENECA AB (SE) | 2012-11-20 | — | — | US | disclosed |
| EP-1912941-B1 | PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-11-14 | — | — | EP | disclosed |
| EP-2402316-A1 | Piperidine derivatives | AstraZeneca AB (Publ) (SE) | 2012-01-04 | — | — | EP | disclosed |
| US-7956070-B2 | Piperidines as chemokine modulators (CCR) | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| US-20080262037-A1 | Piperidine Derivatives for the Treatment of Chemokine Mediated Disease | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | disclosed |
| US-20080207688-A1 | Novel Piperidine Derivatives | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| EP-1625114-B1 | Piperidine derivatives for the the treatment of chemokine or H1 mediated diseases | ASTRAZENECA AB (SE) | 2008-08-27 | — | — | EP | disclosed |
| EP-1912941-A1 | NOVEL PIPERIDINE DERIVATIVES | AstraZeneca AB (SE) | 2008-04-23 | — | — | EP | disclosed |
| US-20070054924-A1 | Novel piperidines as chemokine modulators (ccr) | ASTRAZENECA AB (SE) | 2007-03-08 | — | — | US | disclosed |
| WO-2007011293-A1 | NOVEL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | disclosed |
| EP-1713772-A1 | NOVEL PIPERIDINES AS CHEMOKINE MODULATORS (CCR) | AstraZeneca AB (SE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005073192-A1 | NOVEL PIPERIDINES AS CHEMOKINE MODULATORS (CCR) | ASTRAZENECA AB (SE) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207688-A1 | Novel Piperidine Derivatives | CCR3, CCR1, CCR4 | MAP3K5 1280/4885HRH1 276/4885CCR3 1/4885 |
| US-20070054924-A1 | Novel piperidines as chemokine modulators (ccr) | CCR3, CCR1, CCR4 | MAP3K5 1407/4885HRH1 81/4885CCR3 1/4885 |
| US-20230257365-A1 | SMALL MOLECULE ANDROGEN RECEPTOR PROTEIN DEGRADERS | AR, SHBG, CYP19A1 | MAP3K5 3287/4885HRH1 3646/4885CCR3 4315/4885 |
| US-20130023562-A1 | NOVEL PIPERIDINE DERIVATIVES | CCR3, CCR1, CCR4 | MAP3K5 1280/4885HRH1 276/4885CCR3 1/4885 |
| US-20080262037-A1 | Piperidine Derivatives for the Treatment of Chemokine Mediated Disease | CCR3, CCR1, CCR4 | MAP3K5 1442/4885HRH1 51/4885CCR3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.